AI Article Synopsis
- Percutaneous cardiac catheterization and endovascular procedures can lead to complications at the site where blood vessels are accessed.
- While surgery has been the standard approach to treating these complications, there are now effective non-surgical (percutaneous) methods to address many of these issues.
- Surgical intervention is typically necessary only if the non-surgical methods don't work or aren't appropriate for the situation.
Article Abstract
Percutaneous cardiac catheterization and endovascular procedures are associated with complications at the vascular access site. While surgery has been the traditional treatment for vascular access complications, the current state of the art permits percutaneous management of many access site complications. Surgical repair may be required only when percutaneous methods fail, are not available, or are unsuitable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.10179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Peptide-based vaccine design against Hendra virus through immunoinformatics approach.
Vet Immunol Immunopathol
December 2024
Department of Biochemistry, Bahauddin Zakariya University, Multan 66000, Pakistan. Electronic address:
The Hendra virus (HeV) has resulted in epidemics of respiratory and neurological illnesses in animals. Humans have contracted diseases with high fatality rates as a result of infected domestic animals, but effective vaccinations and therapies are currently not available against HeV. Herein, we analyzed the proteome of HeV and constructed an effective and innovative multi-epitope vaccine using immunoinformatics techniques.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Denali Therapeutics Inc., South San Francisco, CA, USA.
Background: Loss-of-function variants of TREM2 are associated with increased risk of Alzheimer's disease (AD), suggesting that activation of this innate immune receptor may be a useful therapeutic strategy. We've previously described a high-affinity mouse TREM2-activating antibody engineered with a monovalent transferrin receptor (TfR) binding site, termed antibody transport vehicle (ATV), ATV:4D9. Single-cell RNA sequencing and morphometry revealed that ATV:4D9 shifted microglia to metabolically responsive states, which were distinct from those induced by amyloid pathology.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Institute for Biomedical Informatics, Philadelphia, PA, USA.
Background: NIAGADS is a national genomics data repository that facilitates access of genotypic and sequencing data to qualified investigators for the study of the genetics of Alzheimer's disease (AD) and related neurological diseases. Collaborations with large consortia and centers such as the Alzheimer's Disease Genetics Consortium (ADGC), Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Alzheimer's Disease Sequencing Project (ADSP), and the Genome Center for Alzheimer's Disease (GCAD) allow NIAGADS to lead the effort in managing large AD datasets that can be easily accessed and fully utilized by the research community.
Method: NIAGADS is supported by the National Institute on Aging (NIA) under a cooperative agreement.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Northwestern University, Chicago, IL, USA.
Background: Much attention has been paid to the role of the perenchymal brain immune response in Alzheimer's disease (AD). Yet, the peripheral immune system in AD has not been thoroughly studied with modern sequencing methods.
Method: Here, we used a combination of single-cell sequencing strategies, including assay for transposase-accessible chromatin and RNA sequencing, to investigate the epigenetic and transcriptional alterations to the AD peripheral immune system.
Clinical Manifestations.
Alzheimers Dement
December 2024
Neurobehavioral Systems, Inc, Berkeley, CA, USA.
Background: The administration of cognitive tests in patients' homes facilitates access by underserved communities and increases testing capacity and efficiency. However, the validity of at-home computerized cognitive tests is often questioned because of limitations in examiner monitoring, distractions, environmental noise, and potential cheating. Here, we compare performance of the computerized and proctored California Cognitive Assessment Battery (CCAB) when administered at-home or in the laboratory using otherwise identical procedures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!